pDONR223-NTRK3 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-NTRK3
| Articles |
|---|
| NTRK3 kinase fusions in Spitz tumours. Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC. J Pathol. 2016 Nov;240(3):282-290. doi: 10.1002/path.4775. PubMed |
| The oncogenic fusion protein EML4-NTRK3 requires three salt bridges for stability and biological activity. Jiang Z, Meyer AN, Yang W, Donoghue DJ. Heliyon. 2024 Aug 13;10(16):e36278. doi: 10.1016/j.heliyon.2024.e36278. eCollection 2024 Aug 30. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.